EUVIMEDEUVIMED entdecken
Crossref

Efficacy and limitation of nonparoxysmal atrial fibrillation ablation in patients with heart failure with preserved ejection fraction

Akira Fukui iD, Kei Hirota, Kazuki Mitarai, Hidekazu Kondo iD, Takanori Yamaguchi, Tetsuji Shinohara, Naohiko Takahashi

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.16463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Akira Fukui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Clinical Examination, Oita University, Oita, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke Volume, Catheter Ablation, Heart Failure. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). However, the long‐term outcomes and subclinical HF after nonparoxysmal AF ablation in HFpEF patients have not been fully evaluated. Methods and Results One‐hundred‐ninety nonparoxysmal AF patients with left ventricular ejection fraction ≥50% who underwent first‐time AF ablation were studied. HFpEF was diagnosed from a history of congestive HF and/or combined criteria of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) concentration and transthoracic echocardiogram parameters, including average septal‐lateral E/e' and tricuspid regurgitation peak velocity. Ninety‐five patients with HFpEF (HFpEF group) were compared with 95 patients without HF (CNT group). Low voltage area (LVA) was defined as an area with a bipolar electrogram of 5% of the total left atrial surface. The primary endpoint was a composite of death from any cause or hospitalization for worsening HF. The secondary endpoint was subclinical HFpEF defined from NT‐proBNP concentration and average septal‐lateral E/e' or tricuspid regurgitation peak velocity at 6–12 months after the procedure irrespective of the rhythm. Kaplan–Meier curves showed that the primary composite endpoint did not differ between the two groups (mean follow‐up period 707 ± 75 days, log‐rank p = 0.5330). However, significantly more patients in the HFpEF group reached the secondary endpoint (42 [44%] vs. 13 [14%], p < 0.0001). Multivariate analysis revealed that a high preablation NT‐proBNP (odds ratio [OR] 1.001, 95% confidence interval [CI] 1.001–1.002, p = 0.0040) and the existence of LVA (OR 5.983, 95% CI 1.463–31.768, p = 0.0194) independently predicted the secondary endpoint in HFpEF patients.

Conclusion

After nonparoxysmal AF ablation, mortality of HFpEF patients was not inferior compared to patients without coexisting HF. However, subclinical HF occasionally persisted especially in HFpEF patients with a high preprocedure NT‐proBNP concentration and LVA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStroke VolumeCatheter AblationHeart FailureVentricular Function, LeftHumansMaleFemaleAgedMiddle AgedTreatment OutcomeTime FactorsRisk FactorsPeptide FragmentsNatriuretic Peptide, BrainBiomarkersAction PotentialsRetrospective StudiesHeart Rate

Stichwörter der Autor:innen

ablationatrial fibrillationheart failure with preserved ejection fractionleft atrial low voltage area

Substanzen

pro-brain natriuretic peptide (1-76)Peptide FragmentsNatriuretic Peptide, BrainBiomarkers

Autor:innen und Institutionen

  • Department of Cardiology and Clinical Examination, Oita University, Oita, Japan.
  • Department of Cardiovascular Medicine, Saga University, Saga, Japan.

ORCID-Profile: Akira Fukui, Hidekazu Kondo

Zitieren

APA

Fukui, A., Hirota, K., Mitarai, K., Kondo, H., Yamaguchi, T., Shinohara, T., & Takahashi, N. (2025). Efficacy and limitation of nonparoxysmal atrial fibrillation ablation in patients with heart failure with preserved ejection fraction. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16463

Vancouver

Fukui A, Hirota K, Mitarai K, Kondo H, Yamaguchi T, Shinohara T, et al. Efficacy and limitation of nonparoxysmal atrial fibrillation ablation in patients with heart failure with preserved ejection fraction. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16463

BibTeX
@article{Fukui2025,
  author = {Fukui, Akira and Hirota, Kei and Mitarai, Kazuki and Kondo, Hidekazu and Yamaguchi, Takanori and Shinohara, Tetsuji and Takahashi, Naohiko},
  title = {Efficacy and limitation of nonparoxysmal atrial fibrillation ablation in patients with heart failure with preserved ejection fraction},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.16463}
}
Kostenlos starten →